Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026
LCTX vs VTGN: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
LCTX Captures Overall Composite Edge (58.9 HOLD vs 46.5 HOLD), While VTGN Leads 3–2 on Growth & Valuation Pillars
LCTX Overall Winner
6-Pillar Tally: LCTX 2 – 3 VTGN (1 Tie)
Matrix Metrics: LCTX 9 – 1 VTGN
As of Nov 19, 2026, Lineage Cell Therapeutics, Inc. (LCTX) captures the overall head-to-head institutional edge over Vistagen Therapeutics, Inc. (VTGN) on higher Unified Composite conviction (58.9/100 HOLD vs. 46.5/100 HOLD) after splitting the core matrix 9–1 (led by Valuation Multiples, Profitability & Quality), while VTGN wins 3–2 across the 6-pillar growth and valuation breakdown. LCTX trades at $0.82 (30.7x Forward P/E, -280.3% operating margin) versus VTGN at $0.19 (N/M Forward P/E, -2543.1% operating margin).
- Growth vs. Quality Trade-Off: LCTX earns the overall head-to-head edge with a stronger Unified Composite Score (58.9/100 HOLD vs. VTGN 46.5/100 HOLD) and 1.36β · 79% Vol risk profile, whereas VTGN leads top-line expansion (-46.5% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
- Technical & Structure Timing Caution: LCTX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 38.3); meanwhile VTGN trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 49.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About LCTX vs VTGN
LCTX
Head-to-Head Winner
Lineage Cell Therapeutics, Inc.
$0.82
-2.21% 1D
Market Cap
$212.1M
TTM Revenue
$11M
Forward P/E
30.7x
Beta / 30D Vol
1.36β · 79% Vol
Unified Composite Score
58.9
HOLD
Tech 65.0
Fund 54.0
Flow 65.0
Mom 45.0
Weinstein Technical Phase
Markdown · Sell / avoid
VTGN
Vistagen Therapeutics, Inc. Common Stock
$0.19
-6.47% 1D
Market Cap
$9.0M
TTM Revenue
$2.4M
Forward P/E
N/M
Beta / 30D Vol
1.23β · 80% Vol
Unified Composite Score
46.5
HOLD
Tech 30.0
Fund 60.0
Flow 69.0
Mom 54.0
Weinstein Technical Phase
Neutral · Hold
6-Pillar Scorecard Institutional Category Breakdown (LCTX 2 – 3 VTGN)
1. Valuation Multiples
LCTX
Forward P/E
30.7x
N/M
Trailing P/E
30.7x
N/M
PEG Ratio
10.64x
N/M
EV / Revenue
16.3x
N/M
2. Growth & Scale
VTGN
Revenue Growth (YoY)
-61.0%
-46.5%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$11M
$2.4M
Market Cap
$212.1M
$9.0M
3. Profitability & Quality
LCTX
Gross Margin
-95.0%
100.0%
Operating Margin
-280.3%
-2543.1%
Net Profit Margin
16.2%
0.0%
Return on Equity (ROE)
4.3%
-144.9%
4. Balance Sheet & Cash Flow
VTGN
Cash Generation (TTM)
-$24M
-$60M EBITDA
Cash Flow Margin
N/A
N/A
Net Cash / Leverage
$35M Net Cash
$30M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
VTGN
Options Structure Phase
BREAKDOWN
UNCLASSIFIED
Current IV / %ile
896.2% (100th %ile)
274.8% (71st %ile)
Put/Call OI Skew
1.10x (Balanced)
N/A
OBV Trend / Tech Phase
DISTRIBUTION · Markdown
NEUTRAL · Neutral
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: LCTX (9) vs VTGN (1)| Institutional Metric | LCTX | VTGN | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $212.1M | $9.0M | LCTX | |
| Trailing P/E Ratio | 30.7x | N/M | LCTX | |
| Forward P/E Ratio | 30.7x | N/M | LCTX | |
| Revenue Growth (YoY) | -61.0% | -46.5% | VTGN | |
| Operating Margin (TTM) | -280.3% | -2543.1% | LCTX | |
| Net Profit Margin | 16.2% | 0.0% | LCTX | |
| Return on Equity (ROE) | 4.3% | -144.9% | LCTX | |
| 52-Week Range Position | 4% ($1–$2) | 0% ($0–$5) | LCTX | |
| Beta / 30D Volatility | 1.36β · 79% Vol | 1.23β · 80% Vol | LCTX | |
| Unified Institutional Score | 58.9 / 100 (HOLD) | 46.5 / 100 (HOLD) | LCTX | |
| Trailing 12M Revenue (USD) | $11M | $2.4M | Scale | |
| Gross Profit Margin (TTM) | -95.0% | 100.0% | Quality | |
| PEG Ratio & EV / Revenue | 10.64x PEG · 16.3x EV/Rev | N/M PEG · N/M EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$24M ($35M Net Cash) | -$60M EBITDA ($30M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
VTGN +10.2 pp
3M Horizon
VTGN +0.55 pp
6M Horizon
LCTX +32.83 pp
1Y Horizon
LCTX +42.3 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | LCTX Revenue | VTGN Revenue | LCTX Op. Margin | VTGN Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2019 | $0M | N/A | -1106.0% | N/A | LCTX |
| FY2020 | $0M | N/A | -1448.4% | N/A | LCTX |
| FY2021 | $0M | $0M | -1133.6% | -1646.1% | LCTX |
| FY2022 | $10M | $0M | -153.2% | -4308.3% | LCTX |
| FY2023 | $10M | N/A | -276.5% | N/A | LCTX |
| FY2024 | $10M | $0M | -226.1% | -3103.5% | LCTX |
| FY2025 | $10M | $0M | -251.6% | -11517.1% | LCTX |
| FY2026 | N/A | $0M | N/A | -5683.7% | VTGN |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
LCTX
BREAKDOWN
Current IV
896.2%
IV Percentile
100th %ile
Put/Call OI Skew
1.10x (Balanced)
IV Regime
Extreme (>80th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
DISTRIBUTION
Exact LCTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
VTGN
UNCLASSIFIED
Current IV
274.8%
IV Percentile
71st %ile
Put/Call OI Skew
N/A
IV Regime
Elevated (60th–80th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact VTGN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
LCTX Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
VTGN Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ LCTX vs VTGN Key Questions & Quantitative Answers
As of Nov 19, 2026, Lineage Cell Therapeutics, Inc. (LCTX) captures the overall head-to-head institutional edge over Vistagen Therapeutics, Inc. (VTGN) on higher Unified Composite conviction (58.9/100 HOLD vs. 46.5/100 HOLD) after splitting the core matrix 9–1 (led by Valuation Multiples, Profitability & Quality), while VTGN wins 3–2 across the 6-pillar growth and valuation breakdown. LCTX trades at $0.82 (30.7x Forward P/E, -280.3% operating margin) versus VTGN at $0.19 (N/M Forward P/E, -2543.1% operating margin). Growth vs. Quality Trade-Off: LCTX earns the overall head-to-head edge with a stronger Unified Composite Score (58.9/100 HOLD vs. VTGN 46.5/100 HOLD) and 1.36β · 79% Vol risk profile, whereas VTGN leads top-line expansion (-46.5% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: LCTX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 38.3); meanwhile VTGN trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 49.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
VTGN leads the Growth & Scale pillar: LCTX posts -61.0% YoY revenue growth and +0.0% YoY earnings growth on $11M TTM revenue (-95.0% gross margin, -280.3% operating margin), compared with VTGN at -46.5% YoY revenue growth and +0.0% YoY earnings growth on $2.4M TTM revenue (100.0% gross margin, -2543.1% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), LCTX cumulative revenue shifted +0.0% while VTGN shifted N/A. In operating R&D and SG&A reinvestment, LCTX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for VTGN.
LCTX screens cheaper on headline valuation multiples. LCTX trades at 30.7x Forward P/E, 30.7x Trailing P/E, 10.64x PEG, and 16.3x EV/Revenue (unreported FCF margin), whereas VTGN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against LCTX (4.3% ROE) versus VTGN (-144.9% ROE) capital efficiency.
In options market volatility and institutional positioning, LCTX carries 896.2% implied volatility (100th %ile, Extreme (>80th %ile)), a 1.10x (Balanced) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.36β · 79% Vol realized risk). By comparison, VTGN carries 274.8% implied volatility (71st %ile, Elevated (60th–80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.23β · 80% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
VTGN vs LCTX · Reverse Pair
LCTX vs XERS
· Sector Peer
VTGN vs VTVT
· Sector Peer
VTGN vs VSTM
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma
AVGO vs MRVL
· Custom ASIC & Networking